Toll Free: 1-888-928-9744

PharmaEssentia Corporation - Product Pipeline Review - 2015

Published: Jul, 2015 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

PharmaEssentia Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'PharmaEssentia Corporation - Product Pipeline Review - 2015', provides an overview of the PharmaEssentia Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PharmaEssentia Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of PharmaEssentia Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of PharmaEssentia Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the PharmaEssentia Corporation's pipeline products

Reasons to buy

- Evaluate PharmaEssentia Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of PharmaEssentia Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the PharmaEssentia Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of PharmaEssentia Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of PharmaEssentia Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of PharmaEssentia Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 PharmaEssentia Corporation Snapshot 5 PharmaEssentia Corporation Overview 5 Key Information 5 Key Facts 5 PharmaEssentia Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 PharmaEssentia Corporation - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 PharmaEssentia Corporation - Pipeline Products Glance 13 PharmaEssentia Corporation - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 PharmaEssentia Corporation - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 PharmaEssentia Corporation - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 PharmaEssentia Corporation - Drug Profiles 17 (paclitaxel + HM30181A) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ropeginterferon ALFA-2B 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 pegfilgrastim 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 P-1116 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PEG-FSH 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule for Beta Thalassemia and Sickle Cell Anemia 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 PharmaEssentia Corporation - Pipeline Analysis 24 PharmaEssentia Corporation - Pipeline Products by Target 24 PharmaEssentia Corporation - Pipeline Products by Route of Administration 25 PharmaEssentia Corporation - Pipeline Products by Molecule Type 26 PharmaEssentia Corporation - Pipeline Products by Mechanism of Action 27 PharmaEssentia Corporation - Recent Pipeline Updates 28 PharmaEssentia Corporation - Locations And Subsidiaries 31 Head Office 31 Other Locations & Subsidiaries 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
PharmaEssentia Corporation, Key Information 5 PharmaEssentia Corporation, Key Facts 5 PharmaEssentia Corporation - Pipeline by Indication, 2015 7 PharmaEssentia Corporation - Pipeline by Stage of Development, 2015 8 PharmaEssentia Corporation - Monotherapy Products in Pipeline, 2015 9 PharmaEssentia Corporation - Combination Treatment Modalities in Pipeline, 2015 10 PharmaEssentia Corporation - Partnered Products in Pipeline, 2015 11 PharmaEssentia Corporation - Partnered Products/ Combination Treatment Modalities, 2015 12 PharmaEssentia Corporation - Phase III, 2015 13 PharmaEssentia Corporation - Phase II, 2015 14 PharmaEssentia Corporation - Phase I, 2015 15 PharmaEssentia Corporation - Preclinical, 2015 16 PharmaEssentia Corporation - Pipeline by Target, 2015 24 PharmaEssentia Corporation - Pipeline by Route of Administration, 2015 25 PharmaEssentia Corporation - Pipeline by Molecule Type, 2015 26 PharmaEssentia Corporation - Pipeline Products by Mechanism of Action, 2015 27 PharmaEssentia Corporation - Recent Pipeline Updates, 2015 28 PharmaEssentia Corporation, Other Locations 31



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify